SCHEMBL1384166

SCHEMBL1384166

O=C(CO)NCCc1cc(Cl)ccc1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.49
HIF1A Q16665 2/20 0.49
KMT2A Q03164 2/20 0.49
HTT P42858 2/20 0.49
ALOX15 P16050 2/20 0.49
MEN1 O00255 1/20 0.49
SLC22A1 O15245 1/20 0.49
USP2 O75604 1/20 0.49
LMNA P02545 1/20 0.49
HSP90AA1 P07900 1/20 0.49
CYP3A4 P08684 1/20 0.49
MAPT P10636 1/20 0.49
HSPD1 P10809 1/20 0.49
HSPA5 P11021 1/20 0.49
IDO1 P14902 1/20 0.49
ALOX12 P18054 1/20 0.49
CASP1 P29466 1/20 0.49
BLM P54132 1/20 0.49
HSPE1 P61604 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1384164 0.88 HPGD (0.49) HPGDHIF1AKMT2AHTTALOX15
SCHEMBL16795265 0.84 HPGD (0.52) HPGDHIF1AKMT2AHTTALOX15
SCHEMBL13840658 0.75 HIF1A (0.62) HPGDHIF1AKMT2AHTTALOX15
SCHEMBL27653399 0.74 HIF1A (0.52) HPGDHIF1AKMT2AHTTALOX15
SCHEMBL3185618 0.74 ERCC1 (0.54) HPGDHIF1AKMT2AHTTALOX15
SCHEMBL2982937 0.74 ALOX15 (0.65) HPGDHIF1AKMT2AHTTALOX15
SCHEMBL1382347 0.74 PTGER1 (0.54) HPGDKMT2ALMNAALDH1A1
SCHEMBL1418003 0.73 HIF1A (0.59) HPGDHIF1AKMT2AHTTALOX15
SCHEMBL7519491 0.73 ALOX15 (0.59) HPGDHIF1AKMT2AHTTALOX15
SCHEMBL2015757 0.73 MAPT (0.48) HTTALOX15MAPTCDK1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4838121-B2 2011-12-14 JP claimed
EP-1641764-B1 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS NOVARTIS AG (CH) 2011-07-27 EP claimed
EP-2298743-A1 5-membered heterocycle-based P38 kinase inhibitors Novartis AG (CH) 2011-03-23 EP claimed
JP-2007521278-A 2007-08-02 JP claimed
EP-1641764-A1 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS Novartis AG (CH) 2006-04-05 EP claimed
US-20050049288-A1 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS MEREO BIOPHARMA 1 LIMINTED (GB) 2005-03-03 US claimed
WO-2005009973-A1 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS NOVARTIS AG (CH) 2005-02-03 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049288-A1 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS MAPK1, MAP3K1, MAP3K8 HPGD 559/4885HIF1A 1894/4885KMT2A 3472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.